Cresco Labs is a vertically integrated, multi-state cannabis operator in the U.S. that cultivates cannabis, manufactures branded products, and sells through two channels: its own Sunnyside retail dispensary chain and wholesale distribution to third-party dispensaries. Cresco's products span flower, vape, pre-rolls, concentrates, and edibles, sold under a tiered brand portfolio — from value-oriented High Supply, to mainstream Cresco, to premium FloraCal Farms, to lifestyle brands like Good News and Wonder Wellness Co. Cresco operates 73 dispensaries across Illinois, Pennsylvania, Ohio, New York, Massachusetts, and Florida, and its branded wholesale products reach nearly 1,400 third-party dispensaries nationwide. The company reports through two segments: Retail (Sunnyside dispensaries, higher-margin, captures full consumer price) and Wholesale (branded product sales to third-party doors, lower-margin but broader distribution). Cresco deliberately shifts mix toward first-party retail and exclusive products to improve margins. The company's e-commerce platform, sunnyside.shop, drives roughly 75–80% of transactions, providing consumer data that supports pricing and product decisions. Cresco's primary headwind is price compression as cannabis supply grows and markets mature, which Cresco offsets by improving cultivation yields, shifting mix to higher-margin SKUs, and cutting costs. Like all U.S. cannabis operators, Cresco faces a heavy federal tax burden under IRC Section 280E, though a December 2025 executive order to reschedule cannabis from Schedule I to Schedule III could materially improve industry economics.